Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach.

被引：0
|
作者：
Namour, Florence [1 ]
Tasset, Chantal [2 ]
Vayssierre, Beatrice [1 ]
van 't Klooster, Gerben [2 ]
Diderichsen, Paul [3 ]
Cox, Eugene [3 ]
机构：
[1] Galapagos SASU, Romainville, France
[2] Galapagos NV, Mechelen, Belgium
[3] Quantitat Solut, Breda, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1480
引用
收藏
页码：S650 / S651
页数：2
相关论文
共 27 条
  • [21] Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
    Westhovens, R.
    Taylor, P. C.
    Alten, R.
    Pavlova, D.
    Enriquez-Sosa, F.
    Mazur, M.
    Greenwald, M.
    Van der Aa, A.
    Vanhoutte, F.
    Tasset, C.
    Harrison, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) : 998 - 1008
  • [22] Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor, Induces Clinical Remission in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 2 FITZROY Study Interim Analysis
    Vermeire, Severine
    Schreiber, Stefan
    Petryka, Robert
    Kuehbacher, Tanja
    Hebuterne, Xavier
    Roblin, Xavier
    Klopocka, Maria
    Goldis, Adrian
    Wisniewska-Jarosinska, Maria A.
    Baranovsky, Andrei
    Sike, Robert
    Tasset, Chantal T.
    Van der Aa, Annegret
    Harrison, Pille
    GASTROENTEROLOGY, 2016, 150 (04) : S1267 - S1267
  • [23] 12-Week Results Of a Phase 2b Dose-Ranging Study Of Baricitinib, An Oral JAK1/ JAK2 Inhibitor In Japanese Patients With Rheumatoid Arthritis On Background Methotrexate Therapy
    Tanaka, Yoshiya
    Emoto, Kahaku
    Tsujimoto, Mika
    Schlichting, Douglas E.
    Macias, William
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765
  • [24] Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
    Jacqueline M. Tarrant
    René Galien
    Wanying Li
    Lovely Goyal
    Yang Pan
    Rachael Hawtin
    Wangshu Zhang
    Annegret Van der Aa
    Peter C. Taylor
    Rheumatology and Therapy, 2020, 7 : 173 - 190
  • [25] Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
    Tarrant, Jacqueline M.
    Galien, Rene
    Li, Wanying
    Goyal, Lovely
    Pan, Yang
    Hawtin, Rachael
    Zhang, Wangshu
    Van der Aa, Annegret
    Taylor, Peter C.
    RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 173 - 190
  • [26] 12-WEEK RESULTS OF A PHASE 2B DOSE-RANGING STUDY OF LY3009104 (INCB028050), AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    Taylor, P.
    Genovese, M.
    Schlichting, D.
    Beattie, S.
    Gaich, C.
    Gort, R. Fidelus
    Luchi, M.
    Macias, W. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 152 - 153
  • [27] A PHASE 2B/3 RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF UPADACITINIB, A SELECTIVE JAK1 INHIBITOR, IN JAPANESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DMARDS
    Tanaka, Y.
    Takeuchi, T.
    Yamaoka, K.
    Oribe, M.
    Kawano, M.
    Zhou, Y.
    Othman, A. A.
    Pangan, A. L.
    Kitamura, S.
    Matsuda, N.
    Meerwein, S.
    Kameda, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 991 - 992
123